Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX014 Alone and in Combination With Checkpoint Inhibitors in Advanced Solid Tumors
NCT05901285Phase 1Recruiting
- Sponsor
- Vaxiion Therapeutics
- Start
- Nov 2023
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of VAX014 in solid tumor (advanced stage) (2 arms), sponsored by Vaxiion Therapeutics. Primary endpoints: Maximum Tolerated Dose at 21 days, Incidence of Treatment-Emergent Adverse Events at 20 weeks and 3 more. Started Nov 2023; status: recruiting.
02
Drugs
VAX014
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05901285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901285.